亞輝龍(688575.SH):殼多糖酶3樣蛋白1檢測試劑盒取得醫療器械註冊證
格隆匯12月23日丨亞輝龍(688575.SH)公佈,近日,公司控股子公司湖南卓潤生物科技有限公司收到了由湖南省藥品監督管理局簽發的醫療器械註冊證,產品名稱為殼多糖酶3樣蛋白1檢測試劑盒(膠體金法);預期用途用於體外定性檢測人指尖末梢血中的殼多糖酶3樣蛋白1。
本次拿證的殼多糖酶3樣蛋白1檢測試劑盒(膠體金法)可由專業人員、熟練掌握該項操作的患病的非專業人員或其家屬在家中或醫療單位進行殼多糖酶3樣蛋白1的檢測。殼多糖酶3樣蛋白1是酒精性肝硬化、丙型肝炎病毒、乙型肝炎病毒誘導的肝硬化的生物標誌物。本次獲證進一步豐富了公司POCT產品的種類,增強公司在家用醫療器械市場的競爭力,更好地滿足了市場多元化的需求。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.